Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

n as D9902B) clinical trial

designed to assess the safety and efficacy of the investigational

active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with

metastatic androgen-independent prostate cancer. While Dendreon

remains blinded to the data, the independent data monitoring

committee (IDMC) reported to Dendreon a 20 percent reduction in the

risk of death in the PROVENGE arm relative to placebo (Hazard

Ratio= 0.80; 95% Confidence Interval [0.610-1.051]). The IDMC

observed no safety concerns and recommended that the study continue

to its final analysis, which is expected to be completed in mid-2009.

* Presented preclinical data on the Company's lead small molecule

candidate, D-3263, which targets Trp-p8 (a transmembrane cation

channel protein also known as Trp-M8), supporting Trp-p8 as a

therapeutic cancer target. Dendreon plans to file an Investigational

New Drug (IND) application later this year with the U.S. Food and

Drug Administration (FDA) to evaluate D-3263 in a Phase 1 dose

escalation study in cancer.

* Initiated a Phase 2 trial of PROVENGE called ProACT (PROstate Active

Cellular Therapy) or P07-2. The multicenter trial is enrolling 120

patients with metastatic, androgen independent prostate cancer.

* Initiated a Phase 2 trial of PROVENGE in men with localized prostate

cancer who are scheduled to undergo a radical prostatectomy. The

single-center trial called NeoACT (NEOadjuvant Active Cellular

immunoTherapy), or P07-1, which is being conducted at UCSF Helen

Diller Family Comprehensive Cancer Center, is enrolling

approximately 40 patients.

* In lieu of Dendreon's regularly scheduled quarterly conference call,

the Company will present at two upcoming investor c
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2
... magnetic fields and tiny iron-bearing particles to drive healthy ... done in animals, may lead to a new method ... diseased organs in people. , The study team, led ... Chair of Pediatric Cardiology at The Childrens Hospital of ...
... BALTIMORE, Jan. 7 Physicians and ... California will benefit from,a new partnership ... University,Medical Center, providing resources to help ... thereby improving patient care., (Logo: ...
... 7 Cephalon, Inc. (Nasdaq:,CEPH) announced today that the ... the JPMorgan Healthcare Conference are now available on the,"Investor ... On Tuesday, January 8, 2008, Frank Baldino, Jr.,Ph.D., Chairman ... the,Conference beginning at 2:00 p.m. Pacific Time (5 p.m. ...
Cached Biology Technology:Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California 2Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... and the Quebec government have discovered microplastics (in ... of Fisheries and Aquatic Sciences . , The ... industrial cleansers, to which they are commonly added ... buoyancy, they may readily pass through sewage treatment ... the world,s oceans, but have only recently been ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... have fish-like sensations, advanced ship design and more, four ... on Dec. 23 learned they will receive the nation,s ... researchers have been selected for Presidential Early Career Awards ... at a ceremony at the White House early this ...
... forces in a quest to correct a faulty chromosome through ... , used stem cells to correct a defective "ring chromosome" ... correct chromosome abnormalities that give rise to birth defects, mental ... may be possible to use this approach to take cells ...
... a key difference in the biological mechanisms by which the ... study, published in the journal Nature Immunology and ... Life Sciences, centred on STAT1, a protein that can bind ... in the body. STAT-1 responds to interferon signals, hormone-like ...
Cached Biology News:White House lauds ONR-funded researchers for early success 2Nature study discovers chromosome therapy to correct a severe chromosome defect 2Nature study discovers chromosome therapy to correct a severe chromosome defect 3Research uncovers key difference between our bodies' fight against viruses and bacteria 2
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... Antibody against Nonmuscle Myosin II Heavy ... (Stored in TBS + 0.03% Thimerosal) ... peptide SDVNETQPPQSE corresponding to the C-terminus ... B (MHC-B) This antibody is effective ...
... Anti-Mi-2 Immunogen : ... acid residues 474-970 of human ... 7.4, 0.105M NaCl, 0.035% sodium ... Assurance: routinely evaluated by immunoblot ...
Biology Products: